Pneumococcal vaccine polyvalent; contains a total of 575mcg polysaccharides per 0.5mL; soln for IM or SC inj; contains phenol. Pneumovax 23 induces type-specific antibodies that enhance ...

Along with PCV7, the vaccine it replaced, PCV13 is no longer available. PPSV23, known as Pneumovax 23, was approved by the FDA in 1983. It protects against 23 serotypes of pneumococcal bacteria.

The decision was influenced by the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

NA: Not applicable; PCV-7: 7-valent pneumococcal conjugate vaccine; PCV-13: 13-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine.

Dominance of the pneumococcal vaccine category is a race between Merck ... Merck also sells an older shot called Pneumovax 23, which covers 23 serotypes but is based on an older polysaccharide ...

Read all vaccine information available from your health care professional before receiving the vaccine. If you have any questions, ask your health care professional. This vaccine is injected into ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or ...

PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs or bacteria called pneumococcus (pronounced new-mo-kock-us). For more information, see Section 1.

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...